Description
Rimonabant is an inverse agonist at CB1 receptor that was briefly explored as an anti-obesity treatment but has since been withdrawn due to concerns about inducing depressive states in subjects. In animal models, rimonabant decreases food intake. Rimonabant also inhibits binding of antagonists to δ-opioid receptors in vitro. In retinal pigment epithelial cells, rimonabant prevents oxidative injury in a PI3K/Akt-dependent manner.